drugset / Trial / NCT00019708

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00019708

Phase 1 Terminated 45 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
1999-06
Primary completion
2010-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject tanespimycin Unknown Intravenous